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Evolutionary and Functional Analysis
of Celiac Risk Loci Reveals SH2B3
as a Protective Factor against Bacterial Infection
Alexandra Zhernakova,1,2,15 Clara C. Elbers,1,3,15 Bart Ferwerda,4,5 Jihane Romanos,6 Gosia Trynka,6
Patrick C. Dubois,7 Carolien G.F. de Kovel,1 Lude Franke,6,7 Marije Oosting,4,5 Donatella Barisani,8
Maria Teresa Bardella,9,10 Finnish Celiac Disease Study Group11, Leo A.B. Joosten,4,5 Paivi Saavalainen,12
David A. van Heel,7 Carlo Catassi,13,14 Mihai G. Netea,4,5 and Cisca Wijmenga6,*
Celiac disease (CD) is an intolerance to dietary proteins of wheat, barley, and rye. CD may have substantial morbidity, yet it is quite
common with a prevalence of 1%–2% in Western populations. It is not clear why the CD phenotype is so prevalent despite its negative
effects on human health, especially because appropriate treatment in the form of a gluten-free diet has only been available since the
1950s, when dietary gluten was discovered to be the triggering factor. The high prevalence of CD might suggest that genes underlying
this diseasemayhavebeen favored by the process of natural selection.We assessed signatures of selection for ten conﬁrmedCD-associated
loci in several genome-widedata sets, comprising8154 controls from four Europeanpopulations and195 individuals fromaNorthAfrican
population, by studying haplotype lengths via the integrated haplotype score (iHS) method. Consistent signs of positive selection for
CD-associated derived alleles were observed in three loci: IL12A, IL18RAP, and SH2B3. For the SH2B3 risk allele, we also show a difference
in allele frequencydistribution (Fst) betweenHapMapphase II populations. Functional investigationof the effect of the SH2B3genotype in
response to lipopolysaccharide and muramyl dipeptide revealed that carriers of the SH2B3 rs3184504*A risk allele showed stronger acti-
vation of the NOD2 recognition pathway. This suggests that SH2B3 plays a role in protection against bacteria infection, and it provides
a possible explanation for the selective sweep on SH2B3, which occurred sometime between 1200 and 1700 years ago.Celiac disease (CD; MIM 212750) is a common intestinal
inﬂammatory disorder resulting from intolerance to glu-
ten, a major dietary protein of wheat, and related proteins
from barley and rye. CD is the most common food intoler-
ance in the Western world, where it affects 1%–2% of the
population.1 It is also common in North Africa, India,
and the Middle East.1,2 The highest prevalence of CD has
been observed in the Saharawi from North Africa, where
it affects 5.6% of the population. The clinical presentation
of CD can vary from a classical gastrointestinal form, char-
acterized by diarrhea, anemia, and weight loss, to a more
systemic form, presenting with osteoporosis, autoimmune
disease, and low fertility. Mortality in both pediatric and
adult CD patients is signiﬁcantly increased, especially in
undiagnosed and untreated individuals.3–6
Susceptibility to CD has a strong genetic basis. The recur-
rence risk for siblings of CD patients to develop the disease
is about 20 times higher than in the general population,1Complex Genetics Section, Department of Medical Genetics, University Me
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than 80%.7 The strongest genetic risk factors are the
HLA-DQ2 or HLA-DQ8 haplotypes.8 Genome-wide associ-
ation studies (GWASs) and their replications recently led to
the discovery of some 40 non-HLA loci.9–12 To date, CD is
among the best-elucidated complex diseases; approxi-
mately 50% of its genetic susceptibility has been deter-
mined and can now be explained by association to this
set of common HLA and non-HLA genetic variants.
The CD phenotype clearly could have had negative
effects on ﬁtness, given that appropriate treatment in the
form of a gluten-free diet has only been available since
the 1950s, when dietary gluten was discovered to be the
triggering factor. Despite its negative effects on human
health, the CD phenotype is quite common. Evolutionary
processes such as mutations, migration, genetic drift,
and natural selection have shaped the pattern of genetic
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Table 1. Characteristics of the Alleles Associated with Celiac Disease
Chromosome SNP ID Gene
Associated
Allele
Ancestral
or Derived
Derived-
Allele
Frequency
_iHScorr
(UK)
p Value iHS
in European
(UK)
Population
Average
Age of the
Sweep
(Europeans)
Derived-
Allele
Frequency
Saharawi
_iHScorr
Saharawi
p Value
iHS
Saharawi
3 rs6441961 CCR2_3 A derived 0.297 0.728 0.467 n/a 0.249 0.422 0.673
3 rs9811792 IL12A G derived 0.46 1.157 0.247 n/a 0.344 1.174 0.240
3 rs17810546 IL12A,
SCHIP1
G derived 0.128 3.321 0.0009 ~2500 yr 0.06 n/a n/a
2 rs917997 IL18RAP A derived 0.238 2.036 0.042 ~6500 yr 0.154 1.703 0.089
4 rs13151961 IL2, IL21 A ancestral 0.167 0.521 0.603 n/a 0.02 n/a n/a
3 rs1464510 LPP A derived 0.435 0.668 0.504 n/a 0.313 1.104 0.270
2 rs842647 REL A ancestral 0.348 1.022 0.307 n/a 0.136 0.512 0.608
1 rs2816316 RGS1 A derived 0.822 0.042 0.966 n/a 0.756 0.106 0.915
12 rs3184504 SH2B3 A derived 0.468 2.214 0.027 ~1500 yr 0.151 1.224 0.221
6 rs1738074 TAGAP A ancestral 0.577 1.499 0.134 n/a 0.531 1.425 0.154
6 rs2327832 TNFAIP3 G derived 0.23 1.531 0.126 n/a 0.249 0.616 0.538
p values calculated from iHS scores in the UK and the Saharawi populations, and a crude estimation of the average age of the selective sweep for alleles that show
signs of selection in European populations. The OMIM information for genes is as follows: CCR2_3 (MIM 601267 and 601268), SCHIP1 (MIM 611622), LPP (MIM
600700), REL (MIM 164910), RGS1 (MIM 600323), TAGAP (MIM 609667), and TNFAIP3 (MIM 191163).is generally argued to have evolved largely under
neutrality.13–15 The high prevalence of CD could therefore
be the result of drift and purifying selection on its under-
lying genes. Alternatively, the process of natural selection
may have favored genes underlying this disease given
that CD is quite common, not just in a single population
where it might have resulted from a bottleneck and genetic
drift, but also in populations from different continents.
When a genetic variant is under positive selection, it
increases in prevalence in a population and this leaves a
‘‘signature,’’ or pattern, in the human genome. These
signatures can be identiﬁed by comparing them with the
background distribution of genetic variation in humans.
The recently identiﬁed CD susceptibility variants, in com-
bination with the available genome-wide SNP data, pro-
vide the opportunity to study whether genetic variants
underlying this disease have been favored by positive
natural selection. We used existing data from a recently
performed GWAS in ﬁve different populations, compris-
ing 8154 controls from four European populations (UK,
Dutch, Italian, and Finnish) and 195 founder individuals
from Saharawi (N. Africa) CD families, to examine whether
CD susceptibility loci show signs of recent positive selec-
tion by studying haplotype lengths with the Integrated
Haplotype Score (iHS) method.15 To provide insight into
the genetic structure and evolutionary dynamics between
populations, we used the ﬁxation index (Fst) to investigate
the variance in allele frequency among populations.16
For our analysis, we selected the SNPs that were most
strongly associated with the disease from each of the ﬁrst
published ten non-HLA loci that have been shown to be
reproducibly associated with CD in several independent
studies.9–11,17–20 We included a single SNP for nine ofThe Amethe loci (Table 1) and two independently associated SNPs
(r2 ¼ 0.101 in CEU [Utah residents with ancestry from
northern and western Europe]) for the IL12A (MIM
161560) locus (Table 1). European samples were genotyped
on Custom Illumina Human 670-Quad slides, which
included all SNPs present on Hap550 plus 120k CNV
probes (detailed quality control steps described else-
where12). The Saharawi families were genotyped on an Illu-
mina Human 610-Quad platform, which includes the
same 550,000 probes as the Illumina Human 670-Quad
slides. Only founder individuals from the Saharawi
families were included in the analysis. The studies were
approved by the medical-ethics committees of partici-
pating universities. The number of genotyped individuals
from the ﬁve populations included in the analysis is indi-
cated in Table S1, available online.
When an allele is under positive selection, its frequency
rises rapidly in the population over a short time span
and the haplotype carrying the advantageous allele will
be longer relative to haplotypes around equally frequent
alleles that have become common purely by random
genetic drift. To study whether the CD loci are located
in a genomic region with longer-than-expected haplotype
lengths, we used the iHS statistic.15 Genotype data for all
SNPs within a 4 Mb region around the CD susceptibility
alleles were extracted from the genotyped control GWAS
data sets. The Beagle software program was used to phase
haplotypes from genotypes.21 On the basis of chimpanzee
alignment, we assigned an ancestral state to all the SNPs
in the data ﬁles; all the CD susceptibility alleles had known
ancestral states. We used the iHS software (available on-
line) to calculate extended haploblocks around the CD
susceptibility loci in the genome-wide SNP data sets ofrican Journal of Human Genetics 86, 970–977, June 11, 2010 971
all control samples (representing the general population).
A positive iHS score means that haplotypes on the ances-
tral allele background are longer than the derived-allele
background, whereas a negative iHS score means that the
haplotypes on the derived-allele background are longer
than the haplotypes associated with the ancestral allele.
We standardized the iHS values by using derived frequency
bins in a set of ~5,000 randomly chosen SNPs surrounding
the CD susceptibility regions but located at least 500 kb
away from the associated SNP (the 500 kb distance was
selected tomake sure that all SNPs used for standardization
were not in linkage disequilibrium with CD-associated
SNPs). The standardization was performed separately in
each population with control data sets for the European
populations and all the founder samples for the Saharawi
population. After standardization, the iHS distribution
was normal with a mean of 0.00015 and a standard devia-
tion of 0.9996. We calculated the p value with a two-sided
test based on the normal distribution of the iHS values. To
study signs of recent selection around the CD suscepti-
bility loci in HapMap phase II, we used the web-based
tool Haplotter.15
The haplotype structures and iHS values were similar for
the four European populations. Table 1 presents the iHS
values for the UK controls (which form the largest Euro-
pean population) and for the Saharawi. The results of
each separate group are presented in Table S1. In the Sahar-
awi population, the iHS score could be calculated for nine
of the 11 SNPs. The iHS values could not be calculated for
both rs13151961 (IL2/IL21 locus [MIM 147680/MIM
605348]) and rs17810546 (IL12A locus) because of a low
minor-allele frequency.
In the four European populations, we observed con-
sistent and signiﬁcant signs of positive selection for
three of the CD-associated alleles: rs17810546*G (IL12A
locus), rs917997*A (IL18RAP locus [MIM 604509]), and
rs3184504*A (SH2B3 locus [MIM 605093]). For all three
loci, the derived allele showed a signature of positive selec-
tion and this allele was also the CD susceptible allele (i.e.,
risk allele) (Table 1, Table S1). In the Saharawi population,
we observed similar signs of positive selection for
rs3184504*A (SH2B3 locus) and rs917997*A (IL18RAP
locus).
The strongest signatures of selection were observed for
rs17810546*G from the IL12A locus (iHS between 2.923
and3.434; p values between 0.0035 and 0.0006). For esti-
mation of the age of the selective sweep (a crude estimate
of the age of expansion of the derived variant), we ﬁrst
calculated the extended haplotype homozygosity (EHH)13
for the subset of chromosomes carrying the CD risk allele.
To estimate the age, we assumed a star phylogeny of the
haplotypes. The recombination distance r is the distance
in cM between the points where EHH ¼ x to the left and
to the right of the core SNP. For a chosen x, r can be
obtained from the data. When both x and r are then
known, the generation time g can be calculated as g ¼
(ln x / –r)*100. Assuming an average generation length of972 The American Journal of Human Genetics 86, 970–977, June 11,25 years, the age of the selective sweep equals 25g. For
this study, we calculated r for the point where EHH has
dropped to 0.30 (support interval EHH ¼ 0.25 – EHH ¼
0.35). We estimated the age of selective sweep for the
IL12A rs17810546*G to be in the range of 2000–2500
years ago for all four European populations (Table S2A,
Figure S1A).
The associated variant from the IL18RAP locus,
rs917997*A, showed a borderline-signiﬁcant signature of
selection in the European populations (iHS between
1.383 and 2.036; p values between 0.17 and 0.04)
and in the Saharawi population (iHSSaharawi ¼ 1.703;
p ¼ 0.089) (Table 1, Table S1). The frequency of the
rs917997*A risk allele varied from 15% in the Saharawi
population to 19%–24% in the four European populations.
Signs of selection for rs917997*A were also observed
in Asian HapMap samples (iHSAZN_HapMap ¼ 2.115)
(Table S1). The age of a selective sweep of rs917997*A in
the European populations was estimated to be around
6000 years ago (Table S2B, Figure S1B). The rs917997 geno-
type is strongly correlated with IL18RAP expression and
has the lowest level of expression for carriers homozygous
for the risk allele (Figure 1A). Such a cis-regulatory variant
may lead to individuals having different IL18-mediated
innate immune responses to infection. Interestingly,
IL18RAP also confers susceptibility for Crohn’s disease.22
The haplotype containing the SH2B3 rs3184504*A allele
showed consistent signs of positive selection in all Euro-
pean populations (maximum IHSIT ¼ 2.597, p ¼ 0.009)
(Table 1, Table S1, Figure 2, Figure S1C). In the Saharawi
population, the rs3184504*A was also located on an
extremely extended haplotype (Figure S1C); however,
because of the lower allele frequency of this allele (MAF
0.15 in Saharawi versus MAF 0.40–0.49 in European popu-
lations), the iHS p value was not signiﬁcant after correction
for allele frequency. The age of a selective sweep in SH2B3
was estimated to be in the range of 1200–1700 years ago
in the European populations (Table S2C). The haplotype
containing the SH2B3*A allele is associated with many
diseases, including several immune-related diseases (CD,
type 1 diabetes, and rheumatoid arthritis) and metabolic
disorders (hypertension and myocardial infarction).23–27
When a genetic variation is under positive selection,
it increases in prevalence in a population. Because diet,
climate, and pathogen load vary across the world, there
are population differences in selective pressure resulting
in global allele frequency variations. Therefore, allele fre-
quency differences between populations could indicate
that the alleles show signs of selection in a certain popula-
tion (although it could also point toward a population
bottleneck). The Fst is a measure of population differentia-
tion based on data of genetic variation, and the statistic
compares the genetic variability within and between pop-
ulations.28 Without selection, allele frequency differences
between populations are the result of random genetic drift,
which affects all SNPs in the population in a similar way.
We studied the Fst values of the CD susceptibility loci in2010
Figure 1. Functional Consequences of IL18RAP and SH2B3 Genotypes
(A) Individual gene expression correlation of IL18RAP with rs917997 from 1469 PAXgene samples (1240 hybridized to Illumina HT-12
arrays; 229 hybridized to Illumina Ref-8 v2 arrays). Spearman correlation coefﬁcients are shown for HT-12 and Ref-8 v2 data, and meta-
analysis p value results are shown (L.F., unpublished data).
(B) Differences between the SH2B3 genotype after LPS stimulation show a moderately reduced IL-6 cytokine production in PBMCs
isolated from individuals heterozygous for the celiac risk allele.
(C and D) After MDP stimulation, a speciﬁc ligand of the NOD2 innate immune receptor, homozygous individuals carrying the risk allele
showed an increased production of the IL-6 and IL1-b cytokines.
(E) IL-8 production in these individuals also showed an elevated production of the cytokine.
All data in panels (B)–(E) are presented asmeans and standard deviation (SD). The total number of individuals for each SH2B3 genotype is
given under each bar and only the signiﬁcant differences are included (Mann-Whitney U test).the HapMap II populations and compared these values
with an empirical genome-wide distribution.29 Fst is
directly related to the variance in allele frequency amongThe Amepopulations and, conversely, to the degree of resemblance
among individuals within populations. If Fst is small, it
means that the allele frequencies within each populationrican Journal of Human Genetics 86, 970–977, June 11, 2010 973
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Figure 2. Example of EHH Plot of SH2B3
rs3184504 SNP in European and Saharawi
Populations
(A) European (UK controls) population.
(B) Saharawi population.
Blue shows the derived haplotype; red
shows the ancestral haplotype. Included
are 1.4 Mb left and right from rs3184504.
EHH plots for all the selected SNPs and
all the studied populations are presented
in Figure S1A–S1C.are similar; if it is large, it means that the allele frequencies
are different.16 The SH2B3 risk allele had an Fst value of
0.61, which was a signiﬁcant outlier compared to a
genome-wide distribution (p value < 0.05). This allele
shows relatively large between-population frequency dif-
ferences, which could be a sign of differential selection in
HapMap II populations (Table 2). The worldwide allele
frequency distribution of rs3184504 in SH2B3 in the
Human Diversity Project Data is shown in Figure 3.
An important question concerns the mechanism that
underlies the signatures of selection of these gene variants.
It is tempting to speculate that the same alleles that predis-
pose to autoimmune diseases might be protective against
infections—the major cause of mortality in the past. An
example of the interplay between predisposition to auto-
immunity and infections has recently been shown for
the FCGRIIb (MIM 604590) gene polymorphism974 The American Journal of Human Genetics 86, 970–977, June 11, 2010rs1050501, which is associated to
susceptibility to systemic lupus eryth-
ematosus (SLE, [MIM 152700]) and
protection against malaria.30 It is
interesting to note that two of the
genes identiﬁed in our study (IL12A
and IL18RAP) are involved in the acti-
vation of proinﬂammatory cytokine
pathways, and the phenotypic effect
of the selected variants most likely
involves modulation of cytokine
responses. Cytokine responses are
one of the main host defense mecha-
nisms during infections, which exert
a major selective pressure on the
genes of the immune system during
history. SH2B3, the third gene identi-
ﬁed to show signs of recent positive
selection, contains an SH2 domain,
which is common to master regula-
tory genes of innate immunity (such
as SOCS genes).31 Given that an
SH2B3 variant is associated with
several autoimmune and metabolic
disorders, we hypothesized that it
also might play a central role in the
cytokine responses. To test this
hypothesis, we investigated genotypedifferences in inﬂammatory cytokine responses (IL-6, IL-8,
and IL1-b). Venous blood was drawn from 56 European
individuals from the Netherlands from whomwe obtained
informed consent. Peripheral blood mononuclear cells
(PBMCs) were isolated and resuspended in RPMI-1640
medium and adjusted to 5 3 106 cells/ml. A volume of
100 ml was added to round-bottom 96-well plates (Greiner)
and incubated with 100 ml of culture medium (negative
control) or various stimuli. Stimuli added to the PBMCs
were lipopolysaccharide (LPS, 10 ng/ml), muramyl dipep-
tide (MDP, 10 mg/ml), or Pam3Cys (10 mg/ml). IL-6, IL-8,
and IL1-b were measured by commercial ELISA kits (San-
quin, Amsterdam, The Netherlands). The genotype
frequencies were tested for Hardy-Weinberg equilibrium
with a c2 test for goodness of ﬁt. Association between
genotypes (as the independent variable) and IL-6, IL-8,
and IL1b production (as dependent variables) was
Table 2. Fst Measure of Population Differentiation
Chromosome SNP ID Gene Associated Allele Ancestral or Derived Fst HapMapII
3 rs6441961 CCR2_3 A derived 0.19
3 rs9811792 IL12A G derived 0.18
3 rs17810546 IL12A, SCHIP1 G derived 0.20
2 rs917997 IL18RAP A derived 0.27
4 rs13151961 IL2, IL21 A ancestral 0.31
3 rs1464510 LPP A derived 0.21
2 rs842647 REL A ancestral 0.46
1 rs2816316 RGS1 A derived 0.00
12 rs3184504 SH2B3 A derived 0.61a
6 rs1738074 TAGAP A ancestral 0.09
6 rs2327832 TNFAIP3 G derived 0.18
a Significant outlier (p < 0.05) compared with an empirical genome-wide distribution.determined with the Mann-Whitney U test. We also per-
formed trend analyses to test for a dose-response effect
for the CD risk alleles. For this analysis, we used log-trans-
formed data, because the cytokine production levels were
not normally distributed among the tested individuals.
LPS stimulation revealed a moderately (albeit nonsignif-
icantly) decreased cytokine production in heterozygous
rs3184504 individuals compared to individuals homozy-
gous for the nonrisk allele G (Figure 1B). A much more
striking difference in cytokine production was obtained
after cell stimulation with MDP, a component of the pepti-
doglycans present in all bacteria cell walls: the production
of the proinﬂammatory cytokines and IL1-b was 3- to
5-fold higher in homozygous AA individuals, i.e., individ-
uals homozygous for the CD risk allele, compared to indi-
viduals homozygous for the nonrisk G allele (Figure 1D).SNP: rs3184504
Ancestral Allele: C
Derived Allele: T
0˚ 30˚ 60˚ 90˚ 120˚ 15
−30˚
0˚
30˚
60˚ 0
3
The AmeA similar trend was observed for IL-6 and IL-8 (Figures 1C
and 1E). We observed a dose-response relationship of the
risk-allele A with IL1b production (p ¼ 0.034 for trend),
meaning that IL1b production was lowest in individuals
carrying two nonrisk G alleles and that it increased with
each extra risk allele (Figure 1D).
Molecules that contain an SH2 domain in their struc-
ture, like SH2B3, are known to modulate intermolecular
interactions and to inhibit cytokine responses.32 Stimula-
tion of PBMCs with MDP, a speciﬁc ligand of the pattern-
recognition receptor NOD2, shows that cells isolated
from individuals homozygous for the SH2B3 CD risk allele
display an increased proinﬂammatory cytokine produc-
tion. This suggests that the SH2B3 protein has an inhibit-
ing function on the MDP-NOD2-RIP2 signaling pathway,
and this inhibition is diminished in individuals carrying0˚
270˚ 300˚
˚
0˚
Figure 3. Worldwide Allele Frequency
Distribution of rs3184504 in SH2B3
The derived allele is the CD risk allele that
shows a signature of recent selection in our
European study populations. In this ﬁgure,
the rs3184504 alleles are annotated on the
reverse strand.
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the SH2B3 risk allele. The increased cytokine production
observed in these individuals is in line with the interaction
of SH2B3 with the ERK1/2 and p38MAPK pathways33,34;
this interaction in turn mediates NOD2-induced IL1-b
production.35 These functional consequences of different
SH2B3 gene variants suggest, on the one hand, a possible
mechanism of how this polymorphism contributes to
the increased risk of developing immune-related diseases
and, on the other hand, that the cause of the signature
of positive selection should be sought in improved host
defense against infections. The improved response to
bacterial ligands, followed by positive selection, is reminis-
cent of the similar observation reported on the selection of
TIRAP/Mal (MIM 606252) variants, an important adaptor
molecule for the innate immune responses.36
In summary,wehavedemonstrated signsofpositive selec-
tion for three common loci associatedwithCD.Our studyof
SH2B3 reveals the function of the protein in the innate
immune response and provides a possible explanation for
its signature of positive selection. The speciﬁc pressure
that inﬂuenced the selective sweep 1200–1700 years ago
was most likely an infectious disease. Given that NOD2 is
known to be an important receptor for bacterial patho-
gens,37 it is tempting to speculate that SH2B3 is protective
during strong bacterial infection pressures, but more func-
tional studies are needed to prove this relationship.
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